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Diagnosing pleural tuberculosis (pITB) might be difficult due to limited sensitivity of conventional
microbiology tools. As M. tuberculosis (MTB)-specific T cells are recruited into pleural space in pITB,
their detection may provide useful clinical information. To this aim, in addition to standard diagnostic
tests, we used the QuantiFERON-TB Gold In-Tube (QFT-IT) test in blood and pleural effusion (PE)
samples from 48 patients with clinical suspicion of pITB, 18 (37.5%) of whom had confirmed pITB.
Four of them (22.2%) tested positive with a nucleic acid amplification test for MTB. The tuberculin skin
test was positive in most confirmed plTB cases (88.9%). Positive QFT-IT tests were significantly more
frequent in patients with confirmed pITB, as compared to patients with an alternative diagnosis, both
in blood (77.7 vs 36.6%, p=0.006) and in PE samples (83.3% vs 46.6%, p=0.02). In addition, both blood
and PE MTB-stimulated IFN-y levels were significantly higher in plTB patients (p=0.03 and p=0.0049 vs
non-pITB, respectively). In blood samples, QFT-IT had 77.8% sensitivity and 63.3% specificity, resulting
in 56.0% positive (PPV) and 82.6% negative (NPV) predictive values. On PE, QFT-IT sensitivity was
83.3% and specificity 53.3% (PPV 51.7% and NPV 84.2%). The optimal AVe-derived cut-off for MTB-
stimulated pleural IFN-y level was 3.01 IU/mL (77.8% sensitivity, 80% specificity, PPV 68.4% and NPV
82.8%). These data suggest that QFT-IT might have a role in ruling out plTB in clinical practice.
Pleural tuberculosis (pITB) is an extra-pulmonary
manifestation of active tuberculosis (TB),
representing about 4% of all TB cases (I). Despite
the characteristic finding of increased count of
lymphocytes in pleural effusion (PE), confirmation of
pITB diagnosis based on PE analysis is problematic
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due to the low rates of positive microscopic and
culture tests from PE samples (2). Diagnostic
accuracy of culture for Mycobacterium tuberculosis
(MTB) and nucleic acid amplification techniques
(NAAT) in PE ranges from 12 to 70% (2-3) and from
30 to 100% (2, 4), respectively. Biomarkers related
to pleural T cell activation, like adenosine deaminase
(ADA) and unstimulated interferon-gamma (IFN-y),
also have suboptimal performance, with sensitivity
values varying in different studies from 50% to
100% (5-7). Specificity of these biomarkers is
also variable due to the increased levels of both
ADA and IFN-y in para-pneumonic effusions and
lung malignancies. As such, pleural biopsy is still
regarded as the diagnostic "gold standard" for the
diagnosis of pITB, allowing the identification of
typical caseating granulomas (2); however, the
invasiveness of the procedure limits its widespread
use in routine clinical practice.
IFN-y release assays (lGRAs) for diagnosis of
latent TB infection (LTBI) are based on the detection
and quantification of IFN-y released by sensitized
peripheral blood T lymphocytes after in vitro
stimulation with MTB-specific antigens (8). There
are three commercially available assays, the ELISpot-
based T-SPOT.TBTM test (Oxford Immunotec Inc.,
Abingdon, UK) and the two ELISA-based assays,
QuantiFERON-TB Gold and QuantiFERON-TB Gold
In-Tube (QFT-IT) (Cellestis Ltd., Carnegie, Victoria,
Australia). The latter test represents an improvement
of the ELISA-based platform as whole blood is
drawn directly into "vacutainer" tubes pre-coated
with antigens and ready for incubation. IGRAs rely
on the use of two MTB-specific antigens, the Early
Secretory Antigen Target (ESAT)-6 and the Culture
Filtrate Protein (CFP)-IO: QTF-IT also includes
the recombinant protein TB7.7. These antigens are
absent from most environmental non-tuberculous
mycobacteria and from M bovis BCG vaccine strains
(9-10), thus providing IGRA with excellent specificity
(11). Despite the fact that IGRA do not discriminate
LTBI from active TB, pooled sensitivity of blood
assays has recently been estimated to be higher than
80% in detecting active TB disease as a surrogate of
TB infection, at least in developed countries (11- 12).
Some reports indicate that IGRAs might be helpful
in selected cases of pulmonary TB cases (13-17) and
in patients with extra-pulmonary TB, including plTB
and TB meningitis, by detecting the release of IFN-y
by antigen-specific T cells directly at the infection site
(18-25).
MATERIALS AND METHODS
Patients and study design
Fifty-six consecutive HIV-negative patients with
suspected plTB were prospectively enrolled at the
Department of Respiratory Medicine of the University
of Modena, the Department of Clinical and Experimental
Medicine of the Federico II University of Naples, and the
TB Division of the S. Camillo-Forlanini Hospital in Rome,
all in Italy.Patients provided informed consent and the study
was approved by the local Ethics Committees. PE samples
drawn in the context of the routine clinical management
were sent for conventional microbiology [acid-fast bacilli
(AFB) staining and culture for mycobacteria] and TB-
specific DNA amplification (Amplified MTD, Gen-Probe,
San Diego, CA, USA): diagnostic work-up also included
tuberculin skin test (TST) (5 IU PPD, Biocine Test PPD,
Chiron, Siena Italy), interpreted according to current
guidelines (26). To date, the TST threshold used was 10
mm. A cut off of 5 mm was chosen for cases with recent
TB contact (n=3) or with fibrotic changes on chest X-ray
consistent with old TB (n=2). QFT-IT was performed in
all cases on peripheral blood and PE samples, according
to the manufacturer's instructions. Briefly, I mL of blood
or I mL of PE was drawn directly into each of the three
collection tubes pre-coated with saline solution as negative
control (Nil), with phytohaemagglutinin (mitogen, PHA)
as positive control, and with ESAT-6, CFP-lO and TB 7.7:
tubes were shacked and incubated at 37°C in a humidified
atmosphere overnight. The following morning, after
centrifugation, plasma and PE supernatants were harvested
from each tube and stored at 4°C. ELISA-based levels of
IFN-y (IU/mL) were measured with an Automated System
ELISA Reader (Dinex Technologies, West Sussex, UK).
Levels of IFN-y in the negative control tube (Nil) were
subtracted from those recorded in the PHA and TB-specific
tubes before calculating the final amount of the cytokine in
each sample. Results were classified as follows: positive,
if the level of IFN-y was equal or greater than 0.35 IU/mL
in the TB-specific tube, irrespective of the response to the
mitogen; negative, if the concentration of IFN-y was less
than 0.35 IU/mL and equal or greater than 0.50 IU/mL in
the positive control. An indeterminate result was recorded
when the level of PHA-induced IFN-y was less than
0.50 IU/mL and less than 0.35 IU/mL in response to TB
antigens. According to the manufacturer's instructions, if
IFN-y level in the negative control tube was 2::8.0 IU/mL,
the result was discharged as technical fault and excluded
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from the statistical analysis.
Statistical analysis
Categorical and continuous variables were compared
using parametric and non-parametric tests. Statistical
values were expressed as median ± standard deviation
(SD) for non-normally distributed variables. The Mann-
Whitney test was used to compare IFN-y levels across
different groups. Results were considered statistically
significant if the p value was <0.05. The optimal cut-
off values, sensitivity, specificity, positive predictive
value (PPV) and negative predictive value (NPV) of the
IFN-y assay were assessed with receiver operating curve
(ROC) analysis. Analyses were performed using the Stata
software package (Stata Corp, Stata 10.0 software, TX
USA).
RESULTS
Demographic and clinical characteristics of the
study population according to final diagnosis are
reported in Table I. Eight patients were excluded from
the data analysis as QFT-IT scored an indeterminate
result: in 4 cases in blood due to a low response to
PHA and in a further 4 patients on PE, two of them
due to high IFN-y levels in the negative control well.
Patients with QFT-IT indeterminate results included
7 Italians and 1 foreign-born (Philippines) with a
median age of 70 ±14 yrs and a Male:Female ratio
of 6: I. Active TB was excluded in 7 cases; TST
. scored a positive result in one case affected by non-
TB pleuritis and was missing in additional two non-
TB patients. Interpretable QFT-IT results from both
blood and PE samples were therefore available for
48 (85.7%) patients, classified according to their final
diagnosis as follows: (i) definite pITB when culture
was positive for MTB on PE or sputum and/or TB-
NAAT was positive on PE or sputum; (ii) probable
plTB when the diagnosis was based on consistent
clinical and radiological findings and in the presence
of a positive response to anti-TB treatment; (iii)
non-plTB when an alternative diagnosis other than
active TB was made. A diagnosis of either definite or
probable plTB was obtained in 18 (37.5%) patients
(15 of whom were definite plTB). Diagnoses other
than plTB included para-pneumonic effusion
(39.5%), malignancy (16.6%), and other causes
(6.2%). TST was performed on 40 (83.3%) patients,
18 with plTB and 22 with another diagnosis: 16
(88.9%) patients with pITB and 6 (27.3%) non-
TB patients were TST-positive. Results for NAAT
were available for all patients: 7 out of 18 patients
with plTB tested positive with TB-specific NAAT
(4 cases on PE and 3 on sputum), corresponding
to a sensitivity and specificity when applied to PE
samples of 26.6% and 100%, respectively. Overall,
QFT-IT was positive in 14 (77.7%) and 15 (83.3%)
of the 18 pITB cases when performed on blood or
PE samples, respectively. QFT-IT was positive on
pleural fluid of all 15 patients with confirmed plTB,
while 13ofthem also had a positive QFT-IT on blood.
Of the 3 patients with a diagnosis of probable pITB,
QFT-IT was positive in 1 case in blood and in none
in pleural fluid. In patients without plTB, QFT-IT
was positive in II (36.6%) and 14 (46.6%) in blood
and PE samples, respectively. Rates ofpositive QFT-
IT were significantly higher in patients with pITB
both in blood (p=0.006) and PE (p=0.02). MTB-
specific IFN-y levels were significantly higher in PE
Table I. Demographic and clinical characteristics ofthe study population according to final diagnosis.
plTB patients non TB patients
n,(%)
Median age* ± SD, yrs (range)
Males, n (%)
Foreign-borns, n (%)
BeG-vaccinated, n (%)
TST positivity, n (%)
TB-specific NAAT positivity, n (%)
18 (37.5)
32 ± 16 (20-72)
10 (55.5)
7 (38.8)
8 (44.4)
6 (88.9)
7 (46.6)
30 (62.5)
71.5 ±15 (32-94)
22 (73.3)
3 (10)
2(11.1)
6 (27.3)
0(0)
* plTB vs non-TB patients, p< 0.0001; ,'Countries oforigin included Romania. India. Ghana, Egypt, Russia, Somalia.
Pakistan, and Poland.
162 M. LOSI ET AL.
Table II. QFT-IT based interferon-gamma levels in blood and PE samples according to patientfi nal diagnosis.
25% percentile median 75% percentile SD range
Blood QFT-IT IFN-y*
plTB patients 0.36 0.805 2.98 6.44 0.02-25.9 8
non TB patients 0.03 0.205 1.1 8.98 0.00-41.47
PE QFT-IT IFN-y
plTB patients 3.01 13.78 40.38 79.45 0.01-255.04
non TB patients 0.03 0.26 I.I 28.32 0.00- 151.03
*IFN-y levels are expressed as IU/mL
Table III. Performance of pleural and blood QFT-ITaccording to the cut-offlevel in patients with clinical suspicion olplTB.
% sensitivity % specificity %PPV % NPV LR+ LR- %accuracy AVe
PE QFT-IT* 0.78
~O.35 83.3 53.3 5 1.7 84.2 1.78 0.3 1 64.6
~O.91 83,3 70.0 62.5 87.5 2.78 0.24 75.0
~3.01 77.8 80.0 68.4 82.8 3.89 0.28 79.2
Blood QFT-IT* 0.68
~O.35 77.8 63.3 56.0 82.6 2. 12 0.35 68.7
~2.73 33.3 90.0 66.7 69.2 3.33 0.74 68.7
* referred cut-offpoints are expressed as IU/mL
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Fig. I. The Receiver Operating Curve (ROC) fo r TB vs non-TB pleural effusion, indicating that the optimal lFN-y value
is 3,01 IUlmL (77.8% sensitivity. 80% specificity).
than in blood for both plI'B (p=O.005) and non-pl'TB
patients (p=O.04) (Table II): however. M'I'B-spec ific
IFN-y levels in both blood and PE we re significantly
high er in pl'I'B compared to non-pITS cases (p=O.03
and p=O.OO I, respectively) (Table II).
Using the approve d QFT-IT positive cut-off at
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0.35 IFN-y IU/mL, sensmvity and specificity of
blood QFT-IT for plTB were respectively 77.8%
and 63.3% (PPV 56.0%, NPV 82.6%). With the
same cut-off value, sensitivity and specificity of
QFT-IT on PE samples were respectively 83.3%
and 53.3% (PPV 51.7%, NPV 84.2%). Based on
a ROC curve analysis, we estimated the optimal
cut-off point for MTB-specific IFN-y levels in the
QFT-IT assay (Fig. 1): optimal AUC-derived cut-off
in PE was 3.01 IU/mL, providing 77.8% sensitivity
and 80.0% specificity (PPV 68.4%, NPV of 82.8%):
diagnostic accuracy increased from 64.6% to 79.2%.
Conversely, diagnostic accuracy ofQFT-IT remained
unchanged with increased cut-off values in blood
samples (Table III). Finally, the combined use of
TST and PE QFT-IT (with the optimal cut-off point
at 3.01 IU/mL) did not provide additional advantage,
while being associated with increased PPV (77.8%).
DISCUSSION
Standard non-invasive diagnostic tools for
plTB showed suboptimal performance in routine
clinical practice. Some initial evidence suggested
that in vitro assays measuring the release of IFN-y
by effector T cells stimulated with MTB-specific
antigens might help to diagnose extra-pulmonary
active TB cases, in particular if applied to biological
samples representative of the infection site (18-25).
It has been estimated that the frequency of clonally
expanded antigen-specific effector T cells is over
10-fold higher at the site of active plTB and is
theoretically null in patients without TB (27).
The findings of this multi-centre study indicate
that the QFT-IT blood test detects plTB with 77.8%
sensitivity and 63.3% specificity, while the same test
applied to PE samples has 83.3% sensitivity and
53.3% specificity. The combined use of blood and
pleural QFT-IT led to a slight increase of sensitivity
(88.9%), while specificity was not modified. As
predictable, pleural MTB-specific QFT-IT IFN-y
concentrations were significantly higher than those
in blood of patients with plTB, likely reflecting
active recruitment ofMTB-specific IFN-y-producing
T cells to the site of disease. In addition, local
immune-diagnosis by means of pleural QFT-IT was
also performing better compared to TB-specific
NAAT. Conversely, TST diagnostic performance
was higher than expected, which in part may be
due to high probability ofTB infection in our study
population, which included foreign-born cases from
high TB prevalence countries and a high number of
BCG-vaccinated individuals among pITB-patients.
However, this was, in part, not surprising as pooled
sensitivity of TST in studies has been shown to
be no different from that of IGRA, at least in low
prevalence countries (12). Both blood and PE
QFT-IT positive results were obtained in a sizeable
proportion of patients without plTB; nonetheless,
MTB-specific IFN-y levels were significantly higher
in plTB cases. This finding likely reflects LTBI rates
among patients without pITB. As a consequence,
the inclusion of IGRAs in the diagnostic workout
of active plTB cannot be apart from the clinical and
epidemiological setting.
A recent meta-analysis addressing the usefulness
of measurement of total non-specific IFN-y in PE
samples of patients with suspected plTB suggests
this biomarker as a promising diagnostic tool with
an estimated pooled sensitivity and specificity of
89% and 97%, respectively (28). To date, Chegou
and co-workers have shown that ex vivo pleural fluid
IFN-y levels accurately identified TB in all patients
in a high burden area, suggesting IGRA to have a
poor additional diagnostic value (20). Detection
of whole IFN-y was superior to QFT-IT using
blood and pleural fluid (73% and 57% sensitivity,
with 71% and 87% specificity, respectively) and
to QFT-G (the predecessor of QFT-IT) applied to
isolated pleural fluid cells (100% sensitivity and
67% specificity). Similarly, Dheda and co-workers
suggested that total IFN-y is the most accurate test
to distinguishing TB from non-TB pleural effusions
in a cohort of 74 patients in South Africa. Clinical
usefulness of both ELISA- and ELISpot-based tests
measuring TB-specific IFN-y was limited in their
setting by the low accuracy and inability to isolate
sufficient mononuclear cells to correctly perform the
assays (7).
In our study population, although limited in size,
being representative of routine clinical practice,
the interpretation of QFT-IT on PE with a different
cut-off value for positive results improved assay
performance by increasing specificity, PPV and
NPV, while sensitivity was almost unchanged. These
findings, although interesting, have been derived
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from a post-hoc ROC analysis and need to be
validated in prospective large cohorts of patients.
In a previous report, we found that sensitivity and
specificity of the El.lxpot-based assay T-SPOT.TB
applied to PE samples for plTBwere 95% and 76%,
respectively (19). Similar results have been obtained
in a prospective study performed in Taiwan, reporting
high sensitivity and specificity for T-SPOT.TB (22):
furthermore, the performance of the assay was not
reduced by low lymphocyte counts, as MTB-specific
IFN-y T cells were concentrated 8- to 10-fold in
pleural fluid, compared to peripheral blood (22).
Although these findings are limited by the small
sample sizes and by study design, nonetheless, the
two IGRAs may have differential performances
when used with samples other than blood.
Our results confirm that QFT-IT is feasible in
PE samples and may play a role as a rule-out test
to exclude plTB in patients presenting with pleural
effusions of unknown cause. Moreover, the data
suggest that in order to maximize the information
derived from QFT-IT performed on PE, the cut-off
for positive results should be considerably increased:
although this represents an intuitive and potentially
important finding, it will need to be validated in
larger prospective studies.
All Authors declare that no conflict of interest exists.
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